ETST & Cannabis Therapeutics Inc. Announce its Cannabis Cannabinoid-Based Nutraceutical Patent & Generic Pharmaceutical Drug Timeline & Update.
3/6/17, 6:45 AM
Hollywood, March 06, 2017 (GLOBE NEWSWIRE) -- Earth Science Tech, Inc. (OTC
PINK: ETST) ("ETST" or "the Company"), an innovative biotech company focused on
cannabis (industrial hemp) and cannabinoid research and development,
nutraceuticals, pharmaceuticals, and medical devices based company is proud to
announce that its wholly owned subsidiary Cannabis Therapeutics timeline for its
cannabis cannabinoid-based nutraceutical patent and generic pharmaceutical drug
completion.
At a meeting with the company's Advisory Board on Tuesday, February 28th at Le
Centre Québecois d'Innovation en Biotechnologie (CQIB) in Laval, Québec; the
scientists concluded that the improved CBD Hemp Oil food supplement was ready to
move to prototyping, and then to be fast tracked to commercialization. In
addition, two cannabinoid-based generic pharmaceutical drugs will be ready for
pre-market clinical trials related to drug bioavailability by Q3 2017. Depending
on the time needed to properly conduct the clinical trials, both of the
pharmaceutical drugs looks to be completed by the end of 2017 or beginning of
2018. The first or these two generic drugs, an anti-breast cancer drug, is an
important advance for the company as breast cancer affects more women worldwide
than any other cancer. The components of the anti-breast cancer drug that
Cannabis Therapeutics is bringing to market are contained in the World Health
Organization’s current Model List of Essential Medicines (2015). The WHO Model
Complementary List indicates the essential medicines needed to treat priority
diseases, such as breast cancer, by any healthcare system.Other items to note
from the meeting:
Dr. Michel Aubé, CEO and Chief Scientific Officer of ETST and Cannabis Therapeutics, Inc., was in attendance with Dr. Chandra Panchal, Dr. Domenico Fuoco, and Dr. Moutih Rafei.Apart from the three new products for 2017, three other cannabinoid pharmaceutical and nutraceutical product research projects received official start-up approval with product release targeted for YE2018.As predicted, the company also formally launched its R&D partnership with Smart Medicine, Inc. an independent laboratory that provides laboratory and technical services to ETST in their facility at CQIB.The company's Advisory Board agreed to have monthly meetings at CQIB, which are expected to help keep drug development initiatives on schedule.
ETST continuously plans on updating its shareholders on the above mentioned
studies as further progress and development occurs as well as highly anticipated
news we plan to soon unfold.About Earth Science Tech, Inc. (ETST): Earth Science
Tech (www.earthsciencetech.com) is a publicly traded (ETST) unique Science based
Biotechnology company focused on cutting edge Nutraceuticals, Bioceuticals,
Phytoceuticals and Cosmeceuticals for the Health, Wellness and Alternative
Medicine Markets to help improve the quality of life for Consumers Worldwide.
ETST is also dedicated to providing Natural Alternatives to prescription
medications through the use of its cutting edge Nutritional and Dietary
Supplements. This may include products such as its High-Grade Hemp CBD
(Cannabidiol) Oil, Vitamins, Minerals, Herbs, Botanicals, Personal Care
Products, Homeopathies, Functional Foods and other products. These products may
be in various formulations and delivery systems including (but not limited to)
capsules, tablets, soft gels, chewables, liquids, creams, sprays, powders, and
whole herbs. ETST is focused on researching and developing innovative Hemp
extracts and to make them accessible Worldwide. ETST plans to be the premier
supplier of the highest quality and purity of High Grade Hemp CBD (Cannabidiol)
Oil. ETST's primary goal is to advance different High Quality Hemp extracts with
a broad profile of Cannabinoids and additional natural molecules found in
Industrial Hemp and to identify their distinct properties. The company is
dedicated in offering its consumers the finest and purest quality All
Natural-Organic Hemp CBD Oil while never compromising on quality. ETST High
Grade Hemp CBD (Cannabidiol) Oil is classified as "food based" and therefore
perfectly permissible in all 50 states and more than 40 countries. Cannabinoids
(Cannabidiol/CBD) are natural constituents of the Hemp plant and CBD is derived
from Hemp stalk and seed. Hemp oil is a well-known dietary supplement and the
naturally occurring CBD possesses no psychoactive qualities and presents a
continuing stream of overwhelming evidence of significant Wellness benefits.
With no psychoactive ingredient, Hemp CBD Oil is a ready-for-market Hemp-based
Nutraceutical. The United States Food and Drug Administration (FDA) currently
considers non-THC hemp based cannabinoids, including CBD, to be "food based" and
therefore saleable. These new non-psychoactive CBD-rich hemp oil products that
ETST has geared up to market and distribute are beyond reproach. CBD
(cannabidiol), a naturally occurring constituent of the Industrial Hemp plant,
promotes and supports the nutritional health of aging bodies in particular.
Source: US Government Patent #6,630,507 "Cannabinoids as antioxidants and
neuroprotectants." ETST does not grow, sell or distribute any substances that
violate United States Law or the controlled substance act. ETST does sell and
distribute cannabis industrial hemp based products.About Cannabis
Therapeutics: Cannabis Therapeutics, Inc. is a wholly owned subsidiary of Earth
Science Tech, Inc (ETST). Cannabis Therapeutics, Inc. was formed as an emerging
biotechnology company poised to become a world leader in cannabinoid research
and development for a broad line of cannabis cannabinoid-based pharmaceuticals,
nutraceuticals as well as other products & solutions. Cannabis Therapeutics
mission it to help change the healthcare landscape by introducing their
proprietary cannabis-cannabinoid based products made for both the pharmaceutical
and retail consumer markets worldwide. The company is currently working on
finishing the launch of its new corporate website at www.Cannabisthera.com Some
of the R&D that Cannabis Therapeutics will target will be treatments for the
conditions and disorders of: Pain, Chronic Pain, PTSD, Breast Cancer, Brain
Cancer, Anxiety, Depression, Glaucoma, Crohn’s disease, Fatty Liver Diseases,
Diabetes, Parkinson' s Disease, Alzheimer's Disease, Attention Deficit
Hyperactivity Disorder (ADHD), and Drug Addictions among other things. ETST has
chosen to target diseases for which, the benefits of Cannabinoids and/or CBD
(Cannabidiol) have already been demonstrated by different groups of researchers
around the world. However, it is through ETST’s in vitro study with the
University of Central Oklahoma and DV Biologics that results confirm the
positive effectiveness of Earth Science Tech’s CBD (Canabidiol) on breast
cancer, immune cell function, and human brain cells by acting as a
neuroprotectant as shown in its International Application (PCT) for its
Provisional Patent. Thus, as a result by mixing natural molecules and generic
pharmaceutical drugs with Cannabinoids and/or CBD (Cannabidiol) we intend to
increase the effectiveness of Cannabinoids and/or CBD (Cannabidiol) and improve
the treatment of different diseases. The 3 cannabis cannabinoid-based
nutraceutcial patents and 2 generic pharmaceutical drugs will be based on ETST’s
International Application (PCT) for its Provisional Patent named “Cannabidiol
Compositions Including Mixtures and Uses Thereof” was filed on October 8th, 2015
in regards to its Cannabis Hemp CBD (Cannabidiol) Oil. This application claims
the benefit of ETST U.S. Provisional Application N. 62/061,577, filed October 8,
2014 and ETST U.S. Provisional Application No. 62/102,538, filed January 12,
2015.FOOD AND DRUG ADMINISTRATION (FDA) DISCLOSURE: These statements and
products have not been evaluated by the FDA and are not intended to diagnose,
treat or cure any disease. Always check with your physician before starting a
new dietary supplement program. The FDA has not evaluated the validity or
truthfulness of these claims; therefore, we encourage you to review published
researches relating to the benefits and properties of CBD hemp oils and other
CBD products.SAFE HARBOR ACT: Forward-Looking Statements are included within the
meaning of Section 27A of the Securities Act of 1933, and Section 21E of the
Securities Exchange Act of 1934, as amended. All statements regarding our
expected future financial position, results of operations, cash flows, financing
plans, business strategy, products and services, competitive positions, growth
opportunities, plans and objectives of management for future operations,
including words such as "anticipate," "if," "believe," "plan," "estimate,"
"expect," "intend," "may," "could," "should," "will," and other similar
expressions are forward-looking statements and involve risks, uncertainties and
contingencies, many of which are beyond our control, which may cause actual
results, performance, or achievements to differ materially from anticipated
results, performance, or achievements. We are under no obligation to (and
expressly disclaim any such obligation to) update or alter our forward-looking
statements, whether as a result of new information, future events or otherwise.
Investor Relations
Dave Demarest
(305)-546-7640
Earth Science Tech, Inc.
Nickolas S. Tabraue, P/D/COO
(305)-615-2118
Image: Primary Logo
Source: <
